Johnson & Johnson (JNJ)

Shares of Johnson & Johnson broke out of a classic ascending triangle pattern. They have since stalled out at resistance.

Three dividend stocks stand out in July, offering reliable income, attractive yields, and strong fundamentals to help investors navigate market volatility

Johnson & Johnson earnings came in 3% higher than consensus. The company's operating leverage was "slightly diluted by higher tax."

Investors monitor shifting market dynamics and consumer behavior post-pandemic, with Sarat Sethi sticking with Johnson & Johnson amid a positive earnings report. Stephen Weiss picks iShares Bitcoin Trust ETF and Joseph Terranova chooses Intercontinental Exchange, with Piper Sandler raising price target for ICE. Johnson & Johnson's FY2025 earnings guidance rose, while iShares Bitcoin Trust ETF and Intercontinental Exchange shares saw varied movement.

Johnson & Johnson hinted at leveraging tariff delays to maintain its outlook; however, Jim Cramer credited the performance to lower tariffs.

Powell Panic, Pharma Power & a PEW Parade: Wall Street’s Wild Wednesday

Analysts highlighted momentum in oncology and MedTech, with Wells Fargo calling the second-half growth acceleration “achievable” and Morgan Stanley noting visibility risks from drug pricing and tariff policy.

U.S. stocks moved higher today, with the Dow Jones gaining more than 200 points, or 0.5%, to close at 44,254.78.

Johnson & Johnson is back in rally mode after years of post-pandemic normalization and the impact of repositioning, set up to sustain higher prices for years.

Volatility surged across interest rate-sensitive assets Wednesday after reports circulated that President Donald Trump may be preparing to remove Federal Reserve Chair Jerome Powell from his post. The rumors sparked fears over the Fed's independ

Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.

Multinational healthcare company Johnson & Johnson (NYSE:JNJ) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 5.8% year on year to $23.74 billion. The company’s full-year revenue guidance of $93.3 billion at the midpoint came in 2.1% above analysts’ estimates. Its non-GAAP profit of $2.77 per share was 3.2% above analysts’ consensus estimates.

The company also easily beat second-quarter adjusted earnings and sales forecasts.

Johnson & Johnson beat Q2 estimates and raised its 2025 outlook, driven by strong cancer and MedTech sales despite Stelara declines.